Company news

Protagonist Therapeutics, Inc. news in 2026

Protagonist Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Protagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Update

November 5, 2026

Protagonist Therapeutics to Participate in Four Investment Bank Conferences in November 2026

October 27, 2026

Protagonist Therapeutics Announces $300 Million Share Repurchase Program

September 8, 2026

Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026

September 2, 2026

Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera

August 28, 2026

Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 5, 2026

Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress

June 1, 2026

Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026

May 28, 2026

Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)

May 5, 2026

Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 5, 2026

Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration

April 27, 2026

Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsight

April 22, 2026

Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting

March 27, 2026

Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis

March 17, 2026

Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis

March 17, 2026

Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

March 1, 2026

CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

February 25, 2026

Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

February 25, 2026

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026

February 24, 2026

Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026

January 7, 2026

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

January 4, 2026

Decks in 2026